Herman Waldmann

University of Oxford, UK

Title: Explaining infectious tolerance

Herman Waldmann from1994 has been Head of the Dunn School of Pathology in Oxford having previously held the title of Kay Kendall Professor of Therapeutic Immunology in Cambridge. His main interests have been to harness the body’s own tolerance processes therapeutically for acceptance of transplants and reversal of autoimmune diseases. His laboratory was responsible for the discovery and academic development of the CAMPATH-1 antibodies culminating in the licensing of Alemtuzumab. He is also the scientific founder of Tolerx Inc, a company concerned with developing monoclonal antibodies to promote tolerance therapeutically.  He has been a fellow of the British Royal Society since 1990, and a founding fellow of the Academy of Medical Sciences since 1998. In 2008 he was awarded an Honorary Doctorate (DSc) from the University of Cambridge